Artículos del autor

solaci

Chronic Ischemic cardiopathy

FFR and IFR: Are We Talking About the Same Thing?

To evaluate borderline coronary lesions (a 40% to 70% obstruction), determining associated ischemia is paramount. For this...
solaci -
Institutional News

Sign Up for SOLACI-SOCIME 2022 with 25% OFF

You can now take part in one of the most relevant events of the year in interventional...
solaci -
Coronary disease

Using Biolimus-Coated Balloons for Treating Small-Vessel Disease Yields Promising Results

Drug-eluting balloons have demonstrated safety and effectiveness in the treatment of small-vessel coronary artery disease and in-stent...
solaci -
Structural heart disease

TAVR, More Information Supports Its Use

TAVR has been reported beneficial in the treatment of high and intermediate risk patients but, initially, randomized...
solaci -
Acute coronary syndromes

When is the Ideal Timing for NSTE-ACS Percutaneous Intervention?

According to the European Society of Cardiology (ESC Guidelines 2021) an early invasive strategy is recommended (<24h)...
solaci -
Coronary disease

Should We Start Thinking Again About Bioresorbable Stents?

Coronary revascularization with drug-eluting stents (DES) is very frequent, especially in acute coronary syndromes, but these metallic...
solaci -
Institutional News

Save the date Only 2 months for the SOLACI-SOCIME 2022 Congress

August is the month in which we meet again to continue developing interventional cardiology on the continent. Discover...
solaci -
Other

A Nod to Catheter-Guided Thrombolysis in Pulmonary Thromboembolism

Pulmonary thromboembolism (PTE) is the third most frequent cardiovascular disease, with an increasing prevalence over time. The...
solaci -